AI-designed “intrabodies” could unlock new treatments for Alzheimer’s, Parkinson’s and MND
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Essex researchers used AI to convert 672 existing antibodies into 'intrabodies' — engineered fragments designed to survive and function inside human cells and bind disease-related proteins.
- Dr. Caitlin O'Shea and Dr. Gareth Wright led the team that identified electrical charge as the key determinant of intracellular antibody stability, finding typical antibodies carry the 'wrong charge' and clump together inside cells.
- The redesign relied on protein-design software developed by Nobel laureate David Baker and his group, which the Essex team used to recalibrate charge across millions of antibody candidates.
- The resulting intrabodies target proteins implicated in Alzheimer's, Parkinson's, Huntington's and motor neurone disease — conditions affecting over one million people in the UK that currently have no cures.
- Funded by the MND Association and published in Nature Communications, the redesigned molecules will be made freely available to other researchers as laboratory tools.
- MND Association chief scientist Dr. Brian Dickie said the advance overcomes a key barrier to antibody-based neurodegenerative treatments, suggesting the intrabody approach could combine with gene therapy to hit specific molecular targets inside neurones.
Why it matters: The work unlocks the therapeutic potential of millions of existing antibodies that previously couldn't operate inside cells, giving drug hunters a new starting point against four currently incurable neurodegenerative diseases affecting over a million people in the UK — though the molecules are laboratory tools for now, with any clinical application still distant.
Ask SkimNews
